TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23706168

Group type: EXPERIMENTAL
Intervention: HR-HPV prevalence in Trento
Number of subjects: 46900

Group type: EXPERIMENTAL
Intervention: HR-HPV prevalence in Ravenna
Number of subjects: 46900

Group type: EXPERIMENTAL
Intervention: HR-HPV prevalence in 6 centres (Trento, Verona, Florence, Bologna, Imola, Viterbo)
Number of subjects: 46900

Group type: EXPERIMENTAL
Intervention: HR-HPV prevalence in Padua
Number of subjects: 46900

Group type: EXPERIMENTAL
Intervention: HR-HPV prevalence in Turin
Number of subjects: 46900
Study: 21324992

Group type: EXPERIMENTAL
Intervention: Peer support intervention (standardised diabetes care system, recruitment and training of peer supporters, nine group meetings over two years)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 395

Group type: COMPARATOR
Intervention: Control group (standard diabetes care without peer support)
Number of subjects: 395
Study: 18625625

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 49
Study: 17313708

Group type: EXPERIMENTAL
Intervention: High-volume resistance exercise (HVRE) - four sets of eight exercises, twelve repetitions at 12 RM, energy expenditure 1 x 40 MJ
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-volume resistance exercise (LVRE) - two sets of eight exercises, twelve repetitions at 12 RM, energy expenditure 0 x 76 MJ
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control - refrained from exercise
Number of subjects: 10
Study: 15196107

Group type: EXPERIMENTAL
Intervention: NSAID (diclofenac)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Opioid (oxycodone)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Epidural (bupivacaine + fentanyl)
Number of subjects: 51
Study: 11777713

Group type: EXPERIMENTAL
Intervention: Straight phacoemulsification tip (0.9 mm diameter)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Flared phacoemulsification tip (0.76 mm diameter, flaring to 1.02 mm)
Number of subjects: 256
Study: 10530095

Group type: EXPERIMENTAL
Intervention: Braun Oral-B 3D Plaque Remover
Number of subjects: 114

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 114
Study: 7867825

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (hypromellose)
Number of subjects: 10
Study: 2673621

Group type: COMPARATOR
Intervention: 100 mg/day viqualine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 200 mg/day viqualine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both doses of viqualine
Number of subjects: 29
Study: 10942

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 or 2 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31769377

Group type: EXPERIMENTAL
Intervention: Trial-based cognitive therapy (TBCT)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 76
Study: 31359374

Group type: EXPERIMENTAL
Intervention: Video education (personalized videos with specific grade, stage, and tumor subtype information)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard of care educational materials (control group)
Number of subjects: 28
Study: 28046034

Group type: EXPERIMENTAL
Intervention: Intelligent notifications
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Daily notifications within pre-defined time frames
Number of subjects: 77

Group type: COMPARATOR
Intervention: Occasional notifications within pre-defined time frames
Number of subjects: 77
Study: 25753818

Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Number of subjects: 197

Group type: COMPARATOR
Intervention: Expressive suppression
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Negative urgency
Number of subjects: 197
Study: 23877854

Group type: EXPERIMENTAL
Intervention: Stented valve
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stentless valve
Number of subjects: 40
Study: 22105724

Group type: EXPERIMENTAL
Intervention: Deep sedation with intravenous propofol administered by anesthesiologist
Number of subjects: 50
Study: 18725490

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with stenting
Number of subjects: 3051

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 3051
Study: 16227143

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Diclofenac after pre-treatment with bendroflumethiazide and enalapril
Number of subjects: 14
Study: 11799940

Group type: EXPERIMENTAL
Intervention: Scintimammography for dense breasts
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Scintimammography for fatty breasts
Number of subjects: 558
Study: 9813556

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (5‐20 ng/kg/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Phenylephrine infusion (0.7‐2.8 micrograms/kg/min)
Number of subjects: 10
Study: 7659203

Group type: EXPERIMENTAL
Intervention: lormetazepam (1 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: zopiclone (7.5 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 2802120

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg intravenously
Number of subjects: 10

Group type: COMPARATOR
Intervention: No H2-receptor antagonist (control)
Number of subjects: 10
Study: 184913

Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative radiotherapy (group A, 73 patients)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Postoperative radiotherapy only (group B, 64 patients)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Single course of actinomycin D (group I, 80 patients)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Multiple courses of actinomycin D (group II, 80 patients)
Number of subjects: 195
Study: 30503218

Group type: EXPERIMENTAL
Intervention: PACT plus Enhanced Usual Care (PACT+EUC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 24
Study: 28916164

Group type: EXPERIMENTAL
Intervention: Obesity motivational intervention (G1)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Lower intensity consultation, non-motivational group (G2)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Recommendations for weight loss and follow-up in Primary Care Clinic (G3)
Number of subjects: 180
Study: 28002035

Group type: EXPERIMENTAL
Intervention: Omega-3 supplement for 12 weeks
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (no omega-3 supplement)
Number of subjects: 117
Study: 24431097

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 0
Study: 23297557

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Zhizhukuanzhong capsules (ZZKZC)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Combined therapy (Electroacupuncture + ZZKZC)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control (5 mg mosapride three times daily and 20 mg pantoprazole twice daily)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Quality of life scores
Number of subjects: 480
Study: 20377635

Group type: EXPERIMENTAL
Intervention: Coparenting alliance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional indirect model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative predictor model
Number of subjects: 0
Study: 18538974

Group type: EXPERIMENTAL
Intervention: New transdermal fentanyl patch
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard opioid treatment
Number of subjects: 220
Study: 16255878

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 545

Group type: COMPARATOR
Intervention: Early conservative strategy
Number of subjects: 545
Study: 11738537

Group type: EXPERIMENTAL
Intervention: quetiapine 600 mg/day
Number of subjects: 58

Group type: COMPARATOR
Intervention: haloperidol 12 mg/day
Number of subjects: 58
Study: 9672340

Group type: EXPERIMENTAL
Intervention: Audio and visual stimulation
Number of subjects: 37
Study: 7876509

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral therapy (control)
Number of subjects: 0
Study: 2690165

Group type: EXPERIMENTAL
Intervention: Nefazodone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 4730188

Group type: EXPERIMENTAL
Intervention: Watching violent television programmes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Watching violent films
Number of subjects: 0
Study: 31958993

Group type: EXPERIMENTAL
Intervention: Greenbrier Children's Health Opportunities Involving Coordinated Efforts in Schools intervention
Number of subjects: 4633
Study: 31855077

Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 80
Study: 28611374

Group type: EXPERIMENTAL
Intervention: Mycobacterium indicus pranii (MIP)
Number of subjects: 890

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 890
Study: 25862299

Group type: EXPERIMENTAL
Intervention: DSJI (disposable-syringe jet injector)
Number of subjects: 96

Group type: COMPARATOR
Intervention: NS (needle and syringe)
Number of subjects: 96

Group type: COMPARATOR
Intervention: NS
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: DSJI and NS
Number of subjects: 96
Study: 24167166

Group type: EXPERIMENTAL
Intervention: Nonmedical prescription opiate use (NPOU)
Number of subjects: 2135

Group type: EXPERIMENTAL
Intervention: Nonmedical prescription sedative use (NPSU)
Number of subjects: 2135

Group type: EXPERIMENTAL
Intervention: Current home prescription for opioids
Number of subjects: 2135

Group type: EXPERIMENTAL
Intervention: Current home prescription for sedatives
Number of subjects: 2135

Group type: EXPERIMENTAL
Intervention: Receiving an intravenous opioid in the ED
Number of subjects: 2135

Group type: EXPERIMENTAL
Intervention: Dating violence
Number of subjects: 2135

Group type: EXPERIMENTAL
Intervention: Presenting to the ED for a noninjury complaint
Number of subjects: 2135

Group type: EXPERIMENTAL
Intervention: Previous ED visit in the past year
Number of subjects: 2135

Group type: EXPERIMENTAL
Intervention: Other substance use, drinking and driving or riding with a drinking driver
Number of subjects: 2135
Study: 21190903

Group type: EXPERIMENTAL
Intervention: Catheter readjustment after displacement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Initial catheter position without readjustment
Number of subjects: 20
Study: 19101235

Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg/day)
Number of subjects: 7788

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7788
Study: 17544419

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 18
Study: 14534838

Group type: EXPERIMENTAL
Intervention: Free fat grafts (group A)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 99
Study: 11568045

Group type: EXPERIMENTAL
Intervention: Arterial switch operation (ASO)
Number of subjects: 155
Study: 9668931

Group type: EXPERIMENTAL
Intervention: Stage of readiness to change at pretest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticipated positive and negative outcomes of quitting, perceived self-efficacy, and smoking behavior
Number of subjects: 0

Group type: COMPARATOR
Intervention: Number of cigarettes smoked a day, nicotine dependence score, and number of years smoked
Number of subjects: 0
Study: 7816524

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 28523953

Group type: EXPERIMENTAL
Intervention: Intracranial Pressure (ICP) measured immediately after hemicraniectomy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intracranial Pressure (ICP)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Survival at 6 months
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Elevated ICP
Number of subjects: 25
Study: 26501698

Group type: EXPERIMENTAL
Intervention: Expert panel review
Number of subjects: 106

Group type: COMPARATOR
Intervention: No expert panel review
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Expert panel review with all experts or all except 1 voting for randomization
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Expert panel review with 2 experts voting against randomization
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Expert panel review with 3 or 4 experts voting against randomization
Number of subjects: 106
Study: 25052178

Group type: EXPERIMENTAL
Intervention: Internet-based vestibular rehabilitation (VR) intervention
Number of subjects: 262

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Internet-based VR intervention
Number of subjects: 262
Study: 22883656

Group type: EXPERIMENTAL
Intervention: Digital photography as source documentation for skin toxicity assessment
Number of subjects: 552

Group type: COMPARATOR
Intervention: Clinical scoring of skin reactions
Number of subjects: 552
Study: 20513463

Group type: EXPERIMENTAL
Intervention: Recontacted at 1 month
Number of subjects: 605

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 605
Study: 18462105

Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16943538

Group type: EXPERIMENTAL
Intervention: Reduced-dose craniospinal radiotherapy (CSRT) at 23.4 Gy plus adjuvant chemotherapy with lomustine (CCNU), cisplatin, and vincristine
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Reduced-dose craniospinal radiotherapy (CSRT) at 23.4 Gy plus adjuvant chemotherapy with cyclophosphamide, cisplatin, and vincristine
Number of subjects: 379

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as standard treatment)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Patients with areas of frank dissemination
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide arm
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: CCNU regimen
Number of subjects: 379
Study: 12886872

Group type: EXPERIMENTAL
Intervention: irinotecan/cisplatin
Number of subjects: 0
Study: 10743862

Group type: EXPERIMENTAL
Intervention: Polydioxanon (test)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Polylactide acetyltributyl citrate (control)
Number of subjects: 15
Study: 8959151

Group type: EXPERIMENTAL
Intervention: Isocitrate dehydrogenase (IDH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Malate dehydrogenase (MDH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls (sera from non-tuberculous patients)
Number of subjects: 0
Study: 1286488

Group type: EXPERIMENTAL
Intervention: Manidipine (10 to 40 mg daily for 12 months)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Delapril (15 to 60 mg daily for 12 months)
Number of subjects: 45
Study: 2408842

Group type: EXPERIMENTAL
Intervention: Propafenone 450 mg/d
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Disopyramide 600 mg/d
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg/d
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All drugs
Number of subjects: 20
Study: 31365113

Group type: EXPERIMENTAL
Intervention: Enhanced Medical Rehabilitation (EMR)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Standard-of-care rehabilitation
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: EMR
Number of subjects: 229

Group type: COMPARATOR
Intervention: Nontrained therapists
Number of subjects: 229
Study: 29873953

Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole 2 mg/d
Number of subjects: 393

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study: 26854560

Group type: EXPERIMENTAL
Intervention: Predictable group (differential fear conditioning)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Unpredictable group (non-contingent presentation of CS and US)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Unpredictable group
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Predictable group
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 24655228

Group type: EXPERIMENTAL
Intervention: Integrated Telehealth Education and Activation of Mood (I-TEAM)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual care with in-home nursing plus psychoeducation (UC+P)
Number of subjects: 102
Study: 22858403

Group type: EXPERIMENTAL
Intervention: DHEA (100mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 21134044

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA plus 24‐mg/mL cohesive gel
Number of subjects: 90

Group type: COMPARATOR
Intervention: onabotulinumtoxinA alone
Number of subjects: 90

Group type: COMPARATOR
Intervention: 24‐mg/mL cohesive gel alone
Number of subjects: 90
Study: 18062869

Group type: EXPERIMENTAL
Intervention: Hyaluronan-rich transfer medium (n=130)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Conventional transfer medium (n=149)
Number of subjects: 279
Study: 16056117

Group type: EXPERIMENTAL
Intervention: Nurse case managers' interventions to client-initiated telephone calls
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nurse case managers' interventions
Number of subjects: 45
Study: 12368933

Group type: EXPERIMENTAL
Intervention: Lisinopril (ACE inhibitor) for three days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 9539489

Group type: EXPERIMENTAL
Intervention: Angioplasty with assessment of angiographic quality of dilatation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quality of dilatation (optimal vs suboptimal)
Number of subjects: 0
Study: 7872876

Group type: EXPERIMENTAL
Intervention: Retinal Transient Ischemic Attacks (RTIAs)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Hemispheric Transient Ischemic Attacks (HTIAs)
Number of subjects: 129
Study: 2358388

Group type: EXPERIMENTAL
Intervention: Education program (lecture + handout)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Handout only
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6
Study: 382750

Group type: EXPERIMENTAL
Intervention: sulpiride (up to 1,800 mg per day)
Number of subjects: 71

Group type: COMPARATOR
Intervention: chlorpromazine (up to 675 mg)
Number of subjects: 71
Study: 29508498

Group type: EXPERIMENTAL
Intervention: Locator-retained mandibular overdentures with implants in the premolar areas (PM group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Locator-retained mandibular overdentures with implants in the canine regions (CA group)
Number of subjects: 30
Study: 28836851

Group type: EXPERIMENTAL
Intervention: Orange maize consumption
Number of subjects: 88

Group type: COMPARATOR
Intervention: White maize consumption
Number of subjects: 88
Study: 26356086

Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (SSC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Blanket holding (Control)
Number of subjects: 40
Study: 23883812

Group type: EXPERIMENTAL
Intervention: Pollen blocker cream applied three times daily for 30 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo applied three times daily for 30 days
Number of subjects: 30
Study: 21836471

Group type: EXPERIMENTAL
Intervention: Pegylated interferon α‐2b (1.5 μg/kg/wk) plus fixed ribavirin dose (800 mg/d) or weight‐based ribavirin dose (800 to 1400 mg/d) for 24 or 48 weeks
Number of subjects: 4326
Study: 19728183

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 16458458

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact once daily for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 15548461

Group type: EXPERIMENTAL
Intervention: Psychodynamically oriented psychotherapy
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Analytic psychotherapy
Number of subjects: 622

Group type: COMPARATOR
Intervention: All treatment subgroups
Number of subjects: 622
Study: 10665554

Group type: COMPARATOR
Intervention: pyrimethamine-sulphadoxine alone
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: pyrimethamine-sulphadoxine plus one dose of artesunate (4mg/kg bodyweight)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: pyrimethamine-sulphadoxine plus three doses of artesunate (4 mg/kg bodyweight daily for 3 days)
Number of subjects: 600
Study: 9091006

Group type: EXPERIMENTAL
Intervention: Oestrogel (1.5 mg of oestradiol/day) for 24 days each month for 6 months
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Estreva (1.5 mg of oestradiol/day) for 24 days each month for 6 months
Number of subjects: 254
Study: 8374375

Group type: EXPERIMENTAL
Intervention: Glibenclamide regimen 1: usual morning dose in the evening and evening dose before dawn
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Glibenclamide regimen 2: usual morning dose in the evening and evening dose before dawn with a reduction of total dose by a quarter
Number of subjects: 591

Group type: COMPARATOR
Intervention: Control group (non-fasting)
Number of subjects: 591
Study: 3712154

Group type: EXPERIMENTAL
Intervention: Lactose formula
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Sucrose formula
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Polycose formula
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Combined sucrose‐polycose formula
Number of subjects: 85
Study: 31786086

Group type: EXPERIMENTAL
Intervention: Additional ultrasound-accelerated catheter-directed thrombolysis (urokinase with a starting bolus of 250,000 IU in 10 mL NaCl followed by 100,000 IU/h for a maximum of 96 h)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard treatment alone (anticoagulant therapy, compression therapy, early ambulation)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Additional ultrasound-accelerated catheter-directed thrombolysis
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 184
Study: 30940087

Group type: EXPERIMENTAL
Intervention: Single-mode (mail-only or web-only)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mixed-mode (web-mail or mail-web)
Number of subjects: 0